Text Size

Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy

Asada H., Takaoka-Shichijo Y., Nakamura M., Kimura A.


  • 2010
  • Yakugaku Zasshi
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Research and Development Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma, Nara 630-0101, Japan

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022